Allarity Therapeutics (NASDAQ:ALLR) Trading Up 1.6% – What’s Next?

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was up 1.6% during trading on Monday . The stock traded as high as $0.8630 and last traded at $0.8440. Approximately 100,250 shares were traded during mid-day trading, a decline of 42% from the average daily volume of 174,101 shares. The stock had previously closed at $0.8307.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ALLR. Ascendiant Capital Markets upped their target price on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Allarity Therapeutics has an average rating of “Hold” and an average price target of $9.50.

Allarity Therapeutics Trading Up 1.6%

The company has a market cap of $13.57 million, a price-to-earnings ratio of -1.43 and a beta of 0.23. The firm’s fifty day simple moving average is $1.09 and its 200 day simple moving average is $1.26.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. As a group, sell-side analysts expect that Allarity Therapeutics, Inc. will post -78.08 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ALLR. Jane Street Group LLC purchased a new position in shares of Allarity Therapeutics in the 2nd quarter valued at about $27,000. Geode Capital Management LLC lifted its stake in Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after purchasing an additional 16,729 shares during the last quarter. Citadel Advisors LLC acquired a new position in Allarity Therapeutics in the third quarter valued at approximately $149,000. Private Advisor Group LLC purchased a new position in Allarity Therapeutics in the third quarter valued at approximately $441,000. Finally, XTX Topco Ltd acquired a new stake in Allarity Therapeutics during the second quarter worth approximately $51,000. 11.53% of the stock is owned by institutional investors and hedge funds.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.